Ureteral stents for release of urologically beneficial agents
AssigneeBoston Scientific Scimed, Inc.
InventorJianmin Li
Life of this patent
Estimating the term…
Abstract
According to one aspect of the invention, ureteral stents are provided that comprise an elongated stent body and a urologically beneficial agent. The elongated stent body comprises a kidney portion adapted to occupy the kidney of a subject upon implantation, a ureter portion adapted to occupy the ureter of a subject upon implantation, and a bladder portion adapted to occupy the bladder of a subject upon implantation. The ureteral stents of the invention are adapted to release the urologically beneficial agent into the subject. Moreover, the amount of urologically beneficial agent that is released varies along the length of the stent. Other aspects of the invention pertain to methods of forming such stents and methods of using such stents.
Claims22
A ureteral stent comprising an elongated stent body comprised of a solid polymeric composition comprising a polymer and a first urologically beneficial agent, said elongated stent body comprising a kidney portion adapted to occupy the kidney upon implantation, a ureter portion adapted to occupy the ureter upon implantation, and a bladder portion adapted to occupy the bladder upon implantation, wherein said ureter portion constitutes 60-80% of the length of the stent, wherein said ureteral stent is adapted to release said first urologically beneficial agent such that said kidney portion has a higher cumulative total release of said first urologically beneficial agent during the first 7 days of implantation than does the remainder of the stent, wherein a cumulative release of said first urologically beneficial agent from the bladder portion during the first 7 days of implantation is at least two times a cumulative release of said first urologically beneficial agent from the ureter portion during the first 7 days of implantation, and wherein a cumulative release of the first urologically beneficial agent from the kidney portion during the first 7 days of implantation is at least two times the cumulative release of the first urologically beneficial agent from the bladder portion during the first 7 days of implantation.
A ureteral stent comprising an elongated stent body comprised of a solid polymeric composition comprising a polymer and a first urologically beneficial agent, said elongated stent body comprising a kidney portion adapted to occupy the kidney upon implantation, a ureter portion adapted to occupy the ureter upon implantation, and a bladder portion adapted to occupy the bladder upon implantation, wherein said ureter portion constitutes 60-80% of the length of the stent, wherein said ureteral stent is adapted to release said first urologically beneficial agent such that said kidney portion has a higher cumulative total release of said first urologically beneficial agent during the first 7 days of implantation than does the remainder of the stent, wherein an amount of said first urologically beneficial agent in the bladder portion is at least two times an amount of said first urologically beneficial agent in the ureter portion and wherein an amount of said first urologically beneficial agent in the kidney portion is at least two times the amount of said first urologically beneficial agent in the bladder portion.
A ureteral stent comprising an elongated stent body and a first urologically beneficial agent, said elongated stent body comprising a kidney portion adapted to occupy the kidney upon implantation, a ureter portion adapted to occupy the ureter upon implantation, and a bladder portion adapted to occupy the bladder upon implantation, wherein the ureter portion constitutes 60-80% of the length of the stent, wherein at least 50% of a total amount of said first urologically beneficial agent within the ureteral stent is located in the kidney portion of the stent, and (a) wherein an amount of said first urologically beneficial agent located in the bladder portion is at least two times an amount of said first urologically beneficial agent located in the ureter portion and an amount of said first urologically beneficial agent located in the kidney portion is at least two times the amount of said first urologically beneficial agent located in the bladder portion or (b) wherein a concentration of said first urologically beneficial agent in the bladder portion is at least two times a concentration of said first urologically beneficial agent in the ureter portion, and wherein a concentration of said first urologically beneficial agent in the kidney portion is at least two times the concentration of said first urologically beneficial agent in the bladder portion.
A ureteral stent comprising an elongated stent body comprised of a solid polymeric composition containing a polymer and a first urologically beneficial agent, said elongated stent body comprising a kidney portion adapted to occupy the kidney upon implantation, a ureter portion adapted to occupy the ureter upon implantation, and a bladder portion adapted to occupy the bladder upon implantation, wherein the ureter portion constitutes 60-80% of the length of the stent and (a) wherein an amount of said first urologically beneficial agent located in the bladder portion is at least two times an amount of said first urologically beneficial agent located in the ureter portion and an amount of said first urologically beneficial agent located in the kidney portion is at least two times the amount of said first urologically beneficial agent located in the bladder portion or (b) wherein a concentration of said first urologically beneficial agent in the bladder portion is at least two times a concentration of said first urologically beneficial agent in the ureter portion, and wherein a concentration of said first urologically beneficial agent in the kidney portion is at least two times the concentration of said first urologically beneficial agent in the bladder portion.
Dependencies are inferred from the claim text.